647 results about "Sesquiterpene" patented technology

The invention relates to an enantiomorphic amine alkyl sesquiterpene alcohol and glucoside and the medicated salt or solvent thereof, as well as the effect and activity of the composed medicine combination, mainly relating to the medical use in reducing HBV-DNA replication activity. And it has considerably strong inhibiting effect on HBsAG screted by HepG2.2.15 and HBV-DNA replication as compared with positive contrast Lamivudine; and it has obvious inhibition activity to HBV-DNA replication at large dosage (100 mug / mL) and medium dosage(20 mug / mL) as contrasted with Lamivudine, and can be expected to apply to preparing medicines for curing HB virus infection disease.

The invention relates to a hemiterpene derivant 2-Hydroxyilicic acid, as formula (1) 2beta-hydroxy-5alphaH-eudesmane-11(13)-allyl-12-acid and relative compounds which can be used to prepare the drug treating hepatitis B disease. The inventive compound can restrain the copy of hepatitis B surface antigen (HBsAg) and the hepatitis B deoxyribonucleic acid (HBV-DNA), while its HBsAg restrain ability is higher than positive contrast difuradin; in the density as 100mug / ml, 20mug / ml, and 4mug / ml, it can restrain the copy of hepatitis B virus HBV-DNA.

The present invention relates to an eudesmane type sesquiterpene derivative 1 beta-hydroxyilicic acid, namely 1 beta-hydroxy-5 alpha H-eudesmane-11 (13)-ethylene-12-acid, its medicineal salt or solvent compound and its medicine composition and medicinal application for preparing medicine capable of curing hepatitis B virus infective disease and resisting hepatitis B virus. Said invention also provides its chemical structure formula.

The invention discloses a eudesmane typed sesquiterpene acid compound named 5alphaH-eudesmane-11 (13)-alkylene-12 acid, which is characterized by the following: inhibiting the replication of HBsAg and HBV-DNA; fitting for preparing prevention drug of virus B hepatitis; reducing the application in the hepatitis B surface antigen drug.

Medical articles impregnated with antimicrobial compositions containing synergistic combinations of octoxyglycerin and other anti-infective compounds are disclosed. Such medical articles may include urinary catheters, central venous catheters, tracheal catheters, arterial grafts, wound dressings, sutures, or any other medical articles derived from polymeric substrates such as biomedical polyurethane, biomedical polyvinylchloride (PVC), biomedical silicon, biodegradable polymers, polytetrafluoroethylene (PTFE), etc. or from natural products including natural rubber, silk or cotton fiber. Antimicrobial compositions comprising salicylic acid and sesquiterpenoids are also disclosed.

The invention relates to the field of biotechnology and discloses an agilawood production method. The method comprises the steps of first drilling a hole in a trunk of aquilaria malaccensis or aquilaria sinensis, enabling an agilawood inducer formed by plant hormones, inorganic salt and phenethyl alcohol to be added dropwise into the tree in a transfusion mode, then sealing the hole, adding the agilawood inducer dropwise at an interval of 1-2 months, performing treatment for 3-24 months in total, then cutting brown oily matter and yellowish-brown discolored xylem in the trunk, and obtaining agilawood after drying in the sun. The plant hormones are one or more than two of methyl jasmonate, ethephon and 6-BA; and the inorganic salt is one or both of sodium chloride and magnesium chloride. Components of the agilawood inducer are adjusted on the basis of an existing agilawood inducer, a trunk defense system is excited, related enzymes for synthesizing agilawood chemical components are generated and act on phenethyl alcohol, the trunk generates related chemical components in the agilawood, and finally the agilawood is formed by accumulation. According to the method, not only are contents of agilawood oil and sesquiterpenes in the agilawood oil improved, but also contents of alcohol-soluble extracts are improved.

Provided is a composition comprising (a) at least one halogenated compound selected from the group consisting of C3-C5 hydrofluoroolefin, CF3I, and combinations thereof, and (b) an effective stabilizing amount of a sesquiterpene selected from the group consisting of farnesol, farnesene, and mixtures thereof.

A suspension product for reducing wetness under the arm which product comprises in % by weight based on the entire weight of the product: (a) 0.01-20% of a superabsorbent polymer with water absorbing capacity between 10-1000 g water / g superabsorber in the absence of added sodium chloride; (b) 0.05-10% of a sesquiterpene material; (c) 0.05-10% of a small particle size zinc oxide having a particle size range of 0.02-200 microns; (d) 2-88% of a volatile silicone, wherein the product is not made with any separately added water.

A method of sensitizing tumor cells to radiation thereapy, chemotherapy and immunomodulatory thereapy, comprising the step of exposing the tumor cell to an effective amount of at least one monoterpene or sesquiterpene and treating the tumor cell is disclosed.

A method of sensitizing tumor cells to radiation thereapy, chemotherapy and immunomodulatory thereapy, comprising the step of exposing the tumor cell to an effective amount of at least one monoterpene or sesquiterpene and treating the tumor cell is disclosed.

The present invention relates to the genes involved in the biosynthetic pathway for sesquiterpenes of SB type (alpha-santalene, epi-beta-santalene, cis-alpha-bergamotene, trans-alpha-bergamotene and endo-beta-bergamotene,) and for the precursor thereof, Z,Z-farnesyl diphosphate (Z,Z-FPP), involving a Z,Z-FPP synthase and a sesquiterpene SB synthase, and to the uses thereof for producing sesquiterpeniques compounds of SB type.

The invention consists in modifying the levels of accumulation and emission of monoterpenes and sesquiterpenes in citrus as a mechanism to achieve systemic resistance against pathogens or repellency against pests. The alteration of the content of d-limonene and other terpenes is achieved by genetic transformation via the introduction of a gene that encodes an enzyme with d-limonene synthase activity, from a citrus fruit or plant or from another living organism, in antisense or RNAi (RNA interference) configuration. Genetic modification is achieved either by Agrobacterium tumefaciens or any other method of genetic transformation of plants from protoplasts or explants. The construction is incorporated in citrus genotypes or related genera of the family Rutaceae in order to reduce the levels of accumulation and emission of the monoterpene and precursor compounds and / or derivatives, either of leaves or flowers and / or fruit.

The invention relates to the field of algae inhibitors, the invention specifically relates to a sesquiterpene alcohol compound derived from algal epiphytic fungus, a preparation method thereof and anapplication of the sesquiterpene alcohol compound in the aspect of inhibiting microalgae. The specific structural formula is shown in the formula (I). The preparation method comprises the following steps: inoculating a fungal culture medium with Trichoderma virens Y13-3 for fermentation culture, and subjecting a fermentation product to separating and purifying, and the product is namely a sesquiterpene alcohol compound as shown in the formula (I). The median inhibition concentration of the sesquiterpene alcohol compound to the microalga can be up to 1.2 microgram / ml through the microalga activity inhibition experiment.

The present invention provides for a derivative of monoterpene or sesquiterpene, such as a perillyl alcohol derivative. For example, the perillyl alcohol derivative may be a perillyl alcohol carbamate. The perillyl alcohol derivative may be perillyl alcohol conjugated with a therapeutic agent such as a chemotherapeutic agent. The present invention also provides for a method of treating a disease such as cancer, comprising the step of delivering to a patient a therapeutically effective amount of a derivative of monoterpene (or sesquiterpene). The route of administration may vary, and can include, inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

Melampomagnolide B is disclosed as a new antileukemic sesquiterpene. A biotin-conjugated derivative of melampomagnolide B was prepared to elucidate its mechanism of action. Prodrugs of Melampomagnolide B are disclosed.

The invention belongs to the medical technical field, and concretely relates to a preparation method and an application of guaiane-type sesquiterpene. A guaiane-type sesquiterpene compound is 15-hydroxy-2-oxygen-guaiacum-3-alkene-1alpha, 5alpha, 6beta, 7alpha, 10alpha, 11beta hydrogen-12, 6-lactone (15-hydroxy-2-oxo-guaia-3-en-1alpha, 5alpha, 6beta, 7alpha, 10alpha, 11betaH-12, 6-olide, a compound 1), and can be extracted and separated from a whole plant of prenanthes macrophylla franch. Indicated by the research of experiments, the compound has favorable inhibitory activity for a plurality of tumor cells of human body, therefore, the guaiane-type sesquiterpene can be used for preparing antitumor drugs.

The invention relates to a natural Chinese Eaglewood inducer and a Chinese Eaglewood production method, and belongs to the technical field of plant cultivation. Drug effect components of the natural Chinese Eaglewood inducer are composed of a plant endogenous wounding signal, a natural Chinese Eaglewood condensation inducing molecule, a plant nutrition agent and a plant immunizing agent. The Chinese Eaglewood production method comprises the following steps: boring the trunk of an Aquilaria plant, injecting the natural Chinese Eaglewood inducer to Aquilaria malaccensis by using plant transpiration pull, sealing the obtained pore, carrying out treatment for 3-24 months, cutting the trunk, taking a dark brown oily substance and yellowish-brown allochroic xylem, and drying the dark brown oily substance and yellowish-brown allochroic xylem to form Chinese Eaglewood. The drug effect components of the natural Chinese Eaglewood inducer are safe, are natural plant components, and contain no hormones, chemical drugs or artificial perfumes; the Chinese Eaglewood inducer allows the Chinese Eaglewood to be produced in a high-efficiency, high-quality and high-yield manner, and allows standards of National Formulary 2015 to be reached after 3-month Aquilaria malaccensis condensation; and the inducer substantially improves the content of alcohol-soluble extract, Agarotetrol, volatile oil and sesquiterpene.

The invention belongs to natural medicine field and in particular relates to guaiane sesquiterpenoid with general formulaIwhich is distilled from Chinese herb ainsliaeafragrans; wherein R1 is OH or 0- beta-D-GIc; R2 is OH or H; R3 is alpha-H, beta-CH3 or =CH2. The invention further relates to the preparation method of the compound, the medicine combination with the compound as active component, and the application of the compound and the medicine combination thereof in curing acute or chronic inflammation and relevant diseases, including cervicitis, pelvic inflammation, endometritis, upper respiratory tract infection, quinsy as well as faucitis.

Sesquiterpene epoxide compounds (trichothecenes) and methods for administering such compounds to achieve apoptotic ablation of internal organs or internal non-malignant cell populations are disclosed.

Disclosed herein are sweetener compositions comprising at least one sweetener and at least one sweetness enhancer chosen from terpenes (such as sesquiterpenes, diterpenes, and triterpenes), flavonoids, amino acids, proteins, polyols, other known natural sweeteners (such as cinnamaldehydes, selligueians, hematoxylins), secodammarane glycosides, and analogues thereof, wherein the at least one sweetness enhancer is present in the composition in an amount at or below the sweetness detection threshold level of the sweetness ehancer, and the at least one sweetener and the at least one sweetness enhancer are different. Also disclosed herein are methods for enhancing sweetness of a composition, comprising combining at least one sweetener and at least one sweetness enhancer chosen from terpenes (such as sesquiterpenes, diterpenes, and triterpenes), flavonoids, amino acids, proteins, polyols, other known natural sweeteners (such as cinnamaldehydes, selligueians, hematoxylins), secodammarane glycosides, and analogues thereof, wherein the at least one sweetness enhancer is present in the composition in an amount at or below the sweetness detection threshold level of the at least one sweetness enhancer, and the at least one sweetener and the at least one sweetness enhancer are different.

Sesquiterpene epoxide compounds (trichothecenes) and methods for administering such compounds to chemexfoliate selected epidermal cell populations are disclosed.

The invention relates to a preparation method of terpenoid and lignan substances in eucommia ulmoides bark or eucommia ulmoides leaves and an application of the terpenoid and lignan substances in preparation of senile dementia and AD (Alzheimer disease) treatment drugs or healthcare food. The prepared terpenoid substance in the eucommia ulmoides bark or the eucommia ulmoides leaves is one or more of 1-deoxy-delta4,5-eucommiol, 2,3-dyhydroxyl-delta4,5-eucommiol, 5-hydroxyl-3,4-dihydroxymethyl-2-hydroxyethyl-cyclohex- 1-enone-2'-O-beta-D-glucopyranoside), (6R, 7E, 9R)-megastigma-4,7-dien-3-one-9-O-[beta-D-xylopyranos-yl-(1'-6')-beta-D-glucopyranoside, (6S, 7E, 9R)-megastigma-4,7-dien-3-one-9-O-[beta-D-xylopyranos-yl-(1'-6')-beta-D-glucopyranoside] and the like. The prepared lignan substance in the eucommia ulmoides bark or the eucommia ulmoides leaves is one or more of pinoresinol-4,4'-O-beta-D-bis(glucopyranoside), 8-hydroxyl-pinoresinol-4'-O-beta-D-glucopyranoside, lariciresinol-4,4'-O-beta-D- bis(glucopyranoside) and the like. The terpenoid and lignan substances have common or similar structural units such as eucommiol, megastigmane sesquiterpene, bisepoxylignans, single-epoxy lignans and the like, thereby having the similar treatment effect in a human body.

A sesquiterpene-containing film-forming resin and a positive 248 nm photoresist thereof are characterized in that: the film-forming resin is a copolymer prepared by copolymerization of comonomers in a solvent in the presence of a radical initiator, and the comonomers mainly comprise 5-40 parts by weight of substituted styrene and 10-60 parts by weight of a sesquiterpene-containing constitutional unit; and the positive 248 nm photoresist mainly consists of 10-35 parts by weight of the film-forming resin, 0.5-6 parts by weight of a photoinduced acid, 70-90 parts by weight of a solvent and 0.01-0.5 part by weight of an organic base. The film-forming resin of the invention is a new modified film-forming resin prepared by introducing a polymerisable monomer containing a natural product sesquiterpene to a conventional poly(p-hydroxystyrene)-based film-forming resin. The new film-forming resin is capable of increasing transparency of the photoresist at exposure wavelength of 248 nm, improving photosensitivity of the photoresist, increasing adhesive property between HMDS-treated silicon chips, having no influence on photo-etched pattern and no damage to expensive lens of an exposure machine, improving heat resistance of the photoresist and substantially improving anti-etching performance of the photoresist.

The invention relates to sesquiterpene synthases from Patchouli plants (Pogostemon cablin), and methods of their production and use. In one embodiment, the invention provides nucleic acids comprising a nucleotide sequence as described herein that encodes for at least one sesquiterpene synthase. In a further embodiment, the invention also provides for sesquiterpene synthases and methods of making and using these enzymes. For example, sesquiterpene synthases of the invention may be used to convert farnesyl-pyrophosphate to various sesquiterpenes including patchoulol, γ-curcumene and other germacrane-type sesquiterpenes.

Rupestonic acid derivatives are rupestonic acid derivative A- or B-type compounds, prepared through a condensation reaction from starting materials, i.e., a monomer compound of rupestonic acid and an aromatic amine or fatty amine or an organic alcohol, i.e., a fatty alcohol or an aromatic alcohol. Rupestonic acid, which is the monomer compound of sesquiterpene isolated from the plant Xinjiang Artemisia rupestric L., is used as a mother compound. Natural anti-virus lead compound with high activity are discovered by modifying the structure of the monomer compound of rupestonic acid. Activity results of the lead compound showed pharmaceutical application of anti-I, II flu virus and anti-I, II herpes simplex virus infection. These compounds can be used alone or in combination with one or more pharmaceutical acceptable, inert and nontoxic excipients or carries in a pharmaceutical composition.

The present invention discloses a kind of n-hexane extract of stellera chamaejasme and the application of its further separated active compounds A and B as pesticide. Bioactivity test with cabbage worm as target pest shows the n-hexane extract of stellera chamaejasme diluted in 30 times has 72 hr corrected cabbage worm death rate of 100 %, the compound A, 1, 5-diphenyl-3-hydroxy-1-pentanone, has contact killing activity on cabbage worm of 483.4 mg / L (LC50), and the compound B, 4-hydroxy-sesquiterpene-propylene-ester, has contact killing activity on cabbage worm of 530.3 mg / L(LC50). The present invention lays foundation for developing green pesticide with stellera chamaejasme.

The invention discloses an oil sesquiterpene synthase and a coding gene and application thereof. The invention provides a novel sesquiterpene synthase, namely oil sesquiterpene synthase SgSTPS1 and acoding gene thereof. The oil sesquiterpene synthase SgSTPS1 protein can produce an active sesquiterpene synthase after prokaryotic expression. The catalytic substrate FPP produces beta-caryophyllene,isocaryophyllene and alpha-caryophyllene, which can be used for mass production thereof.

The invention relates to a process flow to produce a sesquiterpene inside a golden fungus fermentation liquid and the virtue of the sesquiterpene produced by the golden fungus to reduce the blood sugar, belonging to the biological fermentation and medicine field. The process flow is characterized in that the process flow applicant finds the fermentation liquid and the sesquiterpene produced by the production process are applied on a high blood sugar mouse through an oral administration route, the mouse significantly reduces the blood sugar and the fructosamine, which approves that the golden fungus fermentation liquid and the sesquiterpene are possessed of preparing a health care drink and medicine to reduce the blood sugar; the fermentation liquid color is orange to yellow-brown; the inhibitive rate to the ex vivo non-enzymic glycosylation is up to 72% to 90% with the fermentation liquid and 5mg / ml sesquiterpene. The process flow to produce a sesquiterpene inside a golden fungus fermentation liquid and the virtue of the sesquiterpene produced by the golden fungus to reduce the blood sugar has the advantages of not only creating a fire-new channel to further develop the golden fungus but also providing an ideal Chinese herbal medicine to reduce blood sugar.

The invention relates to an ophiobolin di-sesquiterpene compound and a preparation method and application thereof. The preparation method produces the compound of novel structure by using Aspergillus ustus 094102 (culture collection number: CCTCC M 208153) separated from soil samples of the root system of mangrove plant Bruguiera gymnorrhiza in Touyuan town, Wenchang. Experiments show that the ophiobolin di-sesquiterpene compound can be used as cell proliferation restraining agent or antitumor agent.